|
Active substance |
Sacubitril/Valsartan |
|
Holder |
Novartis Pharma |
|
Status |
Closed |
|
Indication |
Medical Need Program with Entreso (Sacubitril/Valsartan) for the treatment symptomatic chronic heart failure with reduced ejection fraction in adult patients. |
|
Public documents |
|
|
Lasst update |
28/03/2017 |
Entresto®
Last updated on 13/09/2024